Satsuma Pharmaceuticals

$5.82
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.26 (-4.19%) Today

-$0.12 (-2.02%) As of 12:58 PM UTC after-hours

Why Robinhood?

You can buy or sell STSA and other stocks, options, and ETFs commission-free!

About STSA

Satsuma Pharmaceuticals, Inc. Common Stock, also called Satsuma Pharmaceuticals, is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA. The listed name for STSA is Satsuma Pharmaceuticals, Inc. Common Stock.

CEO

John A. Kollins

Employees

Headquarters

San Francisco, California

Founded

2016

Market Cap

101.15M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

318.61K

High Today

$6.27

Low Today

$5.86

Open Price

$6.22

Volume

322.69K

52 Week High

$36.11

52 Week Low

$3.50

STSA Earnings

-$2.26

-$1.51

-$0.75

$0.00

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 9, After Hours